This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NRGN · Western blot design guide
NRGN Western Blot Planning Guide
Plan a NRGN Western blot around the catalog-observed 7.6 kDa band, image-backed A05781-3 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
NRGN Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 7.6 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 15% | |
| Positive control | Caudate | |
| Negative control | Appendix |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 7.6 kDa |
| ⓘ | Localization | Not reported |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated NRGN Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Caudate |
| Gel % | 15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, short transfer |
| Membrane | 0.2 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A05781-3 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected NRGN Western Blot Band Size?
Use the product-observed 7.6 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 7.6 kDa | Matches the authoritative product WB observation. |
| 7.6 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected NRGN appearancePlan around 7.6 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 7.6 kDa; use this as the primary experimental expectation. |
| Calculated mass | 7.6 kDa from UniProt Q92686; retain as context. |
| Gel selection | 15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A05781-3. |
| Situation | Likely cause | Next action |
|---|---|---|
| 7.6 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing NRGN band
A05781-3 · NRGN
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for NRGN Western blot
🧪Use Caudate as the first positive-control candidate and Appendix as the HPA Not detected negative candidate.
Positive control: Caudate (High)
Negative control: Appendix (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for NRGN
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Caudate | Reported tissue cells | High | Protein (HPA) | HPA → |
| Hippocampus | Reported tissue cells | High | Protein (HPA) | HPA → |
| Kidney | Reported tissue cells | High | Protein (HPA) | HPA → |
| Skin | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced NRGN Western Blot Tips
Deeper troubleshooting and optimisation questions for NRGN, answered from its protein features.
Which band should guide the blot?
Use 7.6 kDa, the observation attached to the authoritative A05781-3 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 7.6 kDa expectation.
Which positive control should I start with?
Start with Caudate, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Appendix as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for NRGN Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A05781-3 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
NRGN Western Blot Reagents
Human/Mouse/Rat-reactive NRGN Western blot reagents with authoritative product imagery.
Real WB data
Anti-Neurogranin/NRGN Antibody Picoband®
Cat # A05781-3
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q92686
- Human Protein Atlas — NRGN
- A05781-3 product record
- PMC2734486 — Activation of the brain-specific neurogranin gene in murine T-cell lymphomas by proviral insertional mutagenesis (Gene, 2009)
- PMC3680326 — MicroRNA regulation and its effects on cellular transcriptome in human immunodeficiency virus-1 (HIV-1) infected individuals with distinct viral load and CD4 cell counts (BMC infectious diseases, 2013)
- PMC13457929 — Altered synaptic and astrocytic proteins in Lewy body disorders associated with GBA mutations (Brain communications, 2026)